Categories Earnings, Health Care

Endo International (NASDAQ: ENDP): Q4 2019 Earnings Snapshot

— Endo International plc (NASDAQ: ENDP) reported its fourth-quarter 2019 adjusted earnings of $0.74 per share versus $0.57 per share expected.

— Total revenues declined by 3% to $764.8 million versus $731.43 million expected. This was due to competitive pressures in the Generic Pharmaceuticals segment and the Established Products portfolio of the Branded Pharmaceuticals segment.

Earnings Update by AlphaStreet

— Branded Pharmaceuticals revenues decreased by 2% due to the ongoing generic competition in the Established Products portfolio.

— Specialty Products revenues increased by 15% primarily driven by the continued strong performance of Xiaflex. The demand growth in both the Peyronie’s Disease and Dupuytren’s Contracture indications drove Xiaflex sales higher.

— Revenues of the Sterile Injectables segment increased by 10% to $285 million. This was driven by the continued strong growth of Vasostrict and Adrenalin.

— Generic Pharmaceuticals revenues dropped by 14% due to the continued competitive pressure on commoditized generic products. The ongoing generic competition also hurt the International Pharmaceuticals revenue, which fell by 16%.

— Looking ahead into the full year 2020, the company expects total revenue of $2.72-2.92 billion and adjusted EPS from continuing operations of $2.15-2.40. The consensus estimates EPS of $2.25 on revenue of $2.90 billion.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top